Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study

Published:2024-08 Issue:8 Volume:9 Page:103661
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Chatziioannou E.,Higuita L.M. Serna,Kreft S.,Kandolf L.,Dujovic B.,Reinhardt L.,Tamara E.,Marquez-Rodas I.,Fortuna A.R.F.P.,Nübling A.,Niessner H.,Forschner A.,Garbe C.,Popovic A.,Mirjana B.,Meier F.,Eigentler T.,Leiter U.,Flatz L.,Sinnberg T.,Amaral T.

Publisher

Elsevier BV

Reference44 articles.

1. Treatment of advanced melanoma in 2020 and beyond;Jenkins;J Invest Dermatol,2021

2. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma;Tawbi;N Engl J Med,2022

3. Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy;Atkins;Future Oncol,2022

4. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial;Ascierto;J Clin Oncol,2023

5. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134;Atkins;J Clin Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP